menu search

PCRX / After Plunging -17.19% in 4 Weeks, Here's Why the Trend Might Reverse for Pacira (PCRX)

After Plunging -17.19% in 4 Weeks, Here's Why the Trend Might Reverse for Pacira (PCRX)
The heavy selling pressure might have exhausted for Pacira (PCRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. Read More
Posted: Jan 5 2023, 11:17
Author Name: Zacks Investment Research
Views: 110572

PCRX News  

Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated

By Zacks Investment Research
November 2, 2023

Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated

Pacira (PCRX) announces weaker-than-expected third-quarter 2023 results. The company streamlines its 2023 guidance for net Exparel sales. more_horizontal

Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated

By Zacks Investment Research
August 2, 2023

Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated

Pacira (PCRX) announces weaker-than-expected second-quarter 2023 results. The company updates its 2023 financial guidance. more_horizontal

Here's Why You Should Add Pacira (PCRX) Stock to Your Portfolio

By Zacks Investment Research
May 15, 2023

Here's Why You Should Add Pacira (PCRX) Stock to Your Portfolio

Pacira (PCRX) is witnessing strong growth on the back of its lead product, Exparel. Potential label expansion is set to boost sales in future quarters more_horizontal

Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference

By GlobeNewsWire
May 9, 2023

Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference

TAMPA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fires more_horizontal

Pacira (PCRX) Q1 Earnings Miss Estimates, Revenues Beat

By Zacks Investment Research
May 3, 2023

Pacira (PCRX) Q1 Earnings Miss Estimates, Revenues Beat

Pacira (PCRX) misses on Q1 earnings but beats on revenues, even though volume growth of Exparel is offset by lower selling prices. more_horizontal

Why Is Pacira (PCRX) Down 6% Since Last Earnings Report?

By Zacks Investment Research
March 30, 2023

Why Is Pacira (PCRX) Down 6% Since Last Earnings Report?

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? more_horizontal

Pacira's (PCRX) sNDA for Exparel Accepted for FDA Review

By Zacks Investment Research
March 30, 2023

Pacira's (PCRX) sNDA for Exparel Accepted for FDA Review

The FDA accepts Pacira's (PCRX) sNDA filing, which seeks to expand the label of its pain drug Exparel to include both sciatic and femoral nerve blocks more_horizontal

Pacira's (PCRX) Q4 Earnings Match Estimates, Revenues Fall

By Zacks Investment Research
March 1, 2023

Pacira's (PCRX) Q4 Earnings Match Estimates, Revenues Fall

Pacira BioSciences (PCRX) reports mixed fourth-quarter financial results, where earnings match estimates, but revenues miss the mark. more_horizontal


Search within

Pages Search Results: